Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile, tolerability and sustained ...

In 1872, a young American doctor named Dr. George Huntington published a paper titled “On Chorea,” where he described an ...

Huntington's chorea, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement ...

Huntington's disease, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement ...

Doctors have reported the first successful treatment for Huntington’s disease, describing the breakthrough as a major step ...

I cried with every single patient,” Sung says. “It just was this crazy feeling that, for the patients and families, almost can’t feel real.” The treatment, known as AMT-130, is delivered deep into the ...

After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...

Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...

A one-time gene therapy called AMT-130 helped slow the progression of Huntington's disease by 75%, paving the way for the ...

Huntington's disease is a fatal, hereditary neurological disorder mostly striking people between the ages of 30 and 50.

A GROUNDBREAKING Phase I/II clinical trial has reported that AMT-130, the first gene therapy tested in Huntington’s disease, slowed progression of the condition by 75% compared to a matched cohort, ...